Funding round completed
Dexela Ltd has raised £2.6 million to support the future development and commercialisation of a novel 3D imaging technology, Tomosynthesis, focused initially on the early detection of breast cancer. The main investors included Close Ventures and the London Technology Fund. To date the company has raised more than £4.7 million from grants and two private funding rounds.
While early detection of breast cancer using mammography significantly reduces mortality, the technique is prone to significant rates of both false negative and false positive results, particularly in younger women. Dexela’s technology aims to reduce the number of both false negatives and false positives, and thus detect breast cancer earlier while reducing patient call-backs.
The London-based company has developed methods for acquiring, processing and visualising data from 3D X-ray breast imaging and is collaborating with medical device manufacturers to bring the system into clinical practice. Dexela has raised more than £4.7 million to date via two funding rounds and grants.
Edward Bullard, Chief Executive of Dexela, said: “I am very pleased to have raised these funds with such high quality investors. Over the past year Dexela has achieved considerable progress and we hope to be able to build on this strong foundation in the future. Dexela believes that its technology will contribute significantly to the improvement of breast cancer screening and diagnosis, including outcomes and cost, around the world.”